Vancomycin-resistant enterococci with reduced daptomycin susceptibility in Singapore: prevalence and associated factors
Prevalence of vancomycin-resistant enterococci (VRE) and use of daptomycin are increasing in Asia. To determine the prevalence of daptomycin non-susceptible enterococci (DNSE) and understand factors associated with reduced daptomycin susceptibility in VRE, we conducted a case-control study in a 1600...
Gespeichert in:
| Veröffentlicht in: | Epidemiology and infection 2016-09, Vol.144 (12), p.2540-2545 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2545 |
|---|---|
| container_issue | 12 |
| container_start_page | 2540 |
| container_title | Epidemiology and infection |
| container_volume | 144 |
| creator | CHOW, A. WIN, N. N. NG, P. Y. LEE, W. WIN, M. K. |
| description | Prevalence of vancomycin-resistant enterococci (VRE) and use of daptomycin are increasing in Asia. To determine the prevalence of daptomycin non-susceptible enterococci (DNSE) and understand factors associated with reduced daptomycin susceptibility in VRE, we conducted a case-control study in a 1600-bed adult tertiary hospital in Singapore. All VRE isolates from inpatients in 2012 were tested for daptomycin susceptibility. Patients with VRE isolates of daptomycin minimum inhibitory concentration (MIC) 53 μg/ml were classified as daptomycinreduced susceptible VRE (DRS-VRE) and those with daptomycin MIC 4 μg/ml (DNSE). About half (135, 55%) had reduced susceptibility to daptomycin (MIC 3–4 μg/ml). None in the DS-VRE group had prior exposure to daptomycin. After adjusting for age, gender, comorbidity, hospitalization duration, surgical history, indwelling device use, and duration of antibiotic exposure in the prior 3 months, >1 movement between wards [odds ratio (OR) 0·35, 95% confidence interval (CI) 0·16–0·74, P = 0·006] and minocycline resistance (OR 0·45, 95% CI 0·25–0·84, P = 0·011) were independently associated with DRS-VRE. Our study suggests that daptomycin exposure, >1 movement between wards, and resistance to minocycline, were associated with reduced daptomycin susceptibility in VRE. |
| doi_str_mv | 10.1017/S0950268816000923 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9150451</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>26515768</jstor_id><sourcerecordid>26515768</sourcerecordid><originalsourceid>FETCH-LOGICAL-c482t-216a0d0b44b65b73efb969158b00e36c72bdbb47d6ec093a91bbae2dbe59277d3</originalsourceid><addsrcrecordid>eNqFkUlvFDEQhS0EIkPgB3AAtcSFS0PZ7fWChCI2KRKHBK6Wt0k86mk3ths0_x43E8J24GSp3lfPVfUQeozhBQYsXl6AYkC4lJgDgCLDHbTBlKueUlB30WaV-1U_QQ9K2f1gpLiPTojAgkrKNujys5lc2h9cnPocSizVTLULUw05ueRc7L7Fet3l4BcXfOfNXI90V5biwlyjjWOsh65VLuJ0ZeaUw0N0b2vGEh7dvKfo09s3l2fv-_OP7z6cvT7vHZWk9gRzAx4spZYzK4awtYorzKQFCAN3glhvLRWeBwdqMApbawLxNjBFhPDDKXp19J0Xuw_etbGzGfWc497kg04m6j-VKV7rq_RVt0-AMtwMnt8Y5PRlCaXqfWxbjaOZQlqKxgo4ZYoR8X9UggIqmaINffYXuktLntolVkoSLDlbDfGRcjmVksP2dm4Meo1X_xNv63n6-8K3HT_zbMCTI7ArNeVfOmeYCS6H74Uvq2c</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1808218657</pqid></control><display><type>article</type><title>Vancomycin-resistant enterococci with reduced daptomycin susceptibility in Singapore: prevalence and associated factors</title><source>MEDLINE</source><source>Jstor Complete Legacy</source><source>PubMed Central</source><creator>CHOW, A. ; WIN, N. N. ; NG, P. Y. ; LEE, W. ; WIN, M. K.</creator><creatorcontrib>CHOW, A. ; WIN, N. N. ; NG, P. Y. ; LEE, W. ; WIN, M. K.</creatorcontrib><description>Prevalence of vancomycin-resistant enterococci (VRE) and use of daptomycin are increasing in Asia. To determine the prevalence of daptomycin non-susceptible enterococci (DNSE) and understand factors associated with reduced daptomycin susceptibility in VRE, we conducted a case-control study in a 1600-bed adult tertiary hospital in Singapore. All VRE isolates from inpatients in 2012 were tested for daptomycin susceptibility. Patients with VRE isolates of daptomycin minimum inhibitory concentration (MIC) 53 μg/ml were classified as daptomycinreduced susceptible VRE (DRS-VRE) and those with daptomycin MIC <3 μg/ml classified as daptomycin-susceptible VRE (DS-VRE). Medical records were reviewed for clinical and epidemiological data. None of 243 VRE isolates had MIC >4 μg/ml (DNSE). About half (135, 55%) had reduced susceptibility to daptomycin (MIC 3–4 μg/ml). None in the DS-VRE group had prior exposure to daptomycin. After adjusting for age, gender, comorbidity, hospitalization duration, surgical history, indwelling device use, and duration of antibiotic exposure in the prior 3 months, >1 movement between wards [odds ratio (OR) 0·35, 95% confidence interval (CI) 0·16–0·74, P = 0·006] and minocycline resistance (OR 0·45, 95% CI 0·25–0·84, P = 0·011) were independently associated with DRS-VRE. Our study suggests that daptomycin exposure, >1 movement between wards, and resistance to minocycline, were associated with reduced daptomycin susceptibility in VRE.</description><identifier>ISSN: 0950-2688</identifier><identifier>ISSN: 1469-4409</identifier><identifier>EISSN: 1469-4409</identifier><identifier>DOI: 10.1017/S0950268816000923</identifier><identifier>PMID: 27174845</identifier><language>eng</language><publisher>England: Cambridge University Press</publisher><subject>Aged ; Aged, 80 and over ; Anti-Bacterial Agents - pharmacology ; Antibiotics ; Case-Control Studies ; Comorbidity ; Daptomycin - pharmacology ; Enteropathogens ; Epidemiology ; FDA approval ; Female ; Gram-Positive Bacterial Infections - epidemiology ; Gram-Positive Bacterial Infections - microbiology ; Hospitalization ; Hospitals ; Humans ; Male ; Middle Aged ; Nosocomial infections ; Original Papers ; Patients ; Prevalence ; Risk ; Singapore - epidemiology ; Tertiary Care Centers ; Vancomycin Resistance ; Vancomycin-Resistant Enterococci - drug effects ; Vancomycin-Resistant Enterococci - physiology</subject><ispartof>Epidemiology and infection, 2016-09, Vol.144 (12), p.2540-2545</ispartof><rights>Cambridge University Press 2016</rights><rights>Copyright © Cambridge University Press 2016</rights><rights>Cambridge University Press 2016 2016 Cambridge University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c482t-216a0d0b44b65b73efb969158b00e36c72bdbb47d6ec093a91bbae2dbe59277d3</citedby><cites>FETCH-LOGICAL-c482t-216a0d0b44b65b73efb969158b00e36c72bdbb47d6ec093a91bbae2dbe59277d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/26515768$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/26515768$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,727,780,784,803,885,27924,27925,53791,53793,58017,58250</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27174845$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CHOW, A.</creatorcontrib><creatorcontrib>WIN, N. N.</creatorcontrib><creatorcontrib>NG, P. Y.</creatorcontrib><creatorcontrib>LEE, W.</creatorcontrib><creatorcontrib>WIN, M. K.</creatorcontrib><title>Vancomycin-resistant enterococci with reduced daptomycin susceptibility in Singapore: prevalence and associated factors</title><title>Epidemiology and infection</title><addtitle>Epidemiol Infect</addtitle><description>Prevalence of vancomycin-resistant enterococci (VRE) and use of daptomycin are increasing in Asia. To determine the prevalence of daptomycin non-susceptible enterococci (DNSE) and understand factors associated with reduced daptomycin susceptibility in VRE, we conducted a case-control study in a 1600-bed adult tertiary hospital in Singapore. All VRE isolates from inpatients in 2012 were tested for daptomycin susceptibility. Patients with VRE isolates of daptomycin minimum inhibitory concentration (MIC) 53 μg/ml were classified as daptomycinreduced susceptible VRE (DRS-VRE) and those with daptomycin MIC <3 μg/ml classified as daptomycin-susceptible VRE (DS-VRE). Medical records were reviewed for clinical and epidemiological data. None of 243 VRE isolates had MIC >4 μg/ml (DNSE). About half (135, 55%) had reduced susceptibility to daptomycin (MIC 3–4 μg/ml). None in the DS-VRE group had prior exposure to daptomycin. After adjusting for age, gender, comorbidity, hospitalization duration, surgical history, indwelling device use, and duration of antibiotic exposure in the prior 3 months, >1 movement between wards [odds ratio (OR) 0·35, 95% confidence interval (CI) 0·16–0·74, P = 0·006] and minocycline resistance (OR 0·45, 95% CI 0·25–0·84, P = 0·011) were independently associated with DRS-VRE. Our study suggests that daptomycin exposure, >1 movement between wards, and resistance to minocycline, were associated with reduced daptomycin susceptibility in VRE.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibiotics</subject><subject>Case-Control Studies</subject><subject>Comorbidity</subject><subject>Daptomycin - pharmacology</subject><subject>Enteropathogens</subject><subject>Epidemiology</subject><subject>FDA approval</subject><subject>Female</subject><subject>Gram-Positive Bacterial Infections - epidemiology</subject><subject>Gram-Positive Bacterial Infections - microbiology</subject><subject>Hospitalization</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nosocomial infections</subject><subject>Original Papers</subject><subject>Patients</subject><subject>Prevalence</subject><subject>Risk</subject><subject>Singapore - epidemiology</subject><subject>Tertiary Care Centers</subject><subject>Vancomycin Resistance</subject><subject>Vancomycin-Resistant Enterococci - drug effects</subject><subject>Vancomycin-Resistant Enterococci - physiology</subject><issn>0950-2688</issn><issn>1469-4409</issn><issn>1469-4409</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkUlvFDEQhS0EIkPgB3AAtcSFS0PZ7fWChCI2KRKHBK6Wt0k86mk3ths0_x43E8J24GSp3lfPVfUQeozhBQYsXl6AYkC4lJgDgCLDHbTBlKueUlB30WaV-1U_QQ9K2f1gpLiPTojAgkrKNujys5lc2h9cnPocSizVTLULUw05ueRc7L7Fet3l4BcXfOfNXI90V5biwlyjjWOsh65VLuJ0ZeaUw0N0b2vGEh7dvKfo09s3l2fv-_OP7z6cvT7vHZWk9gRzAx4spZYzK4awtYorzKQFCAN3glhvLRWeBwdqMApbawLxNjBFhPDDKXp19J0Xuw_etbGzGfWc497kg04m6j-VKV7rq_RVt0-AMtwMnt8Y5PRlCaXqfWxbjaOZQlqKxgo4ZYoR8X9UggIqmaINffYXuktLntolVkoSLDlbDfGRcjmVksP2dm4Meo1X_xNv63n6-8K3HT_zbMCTI7ArNeVfOmeYCS6H74Uvq2c</recordid><startdate>20160901</startdate><enddate>20160901</enddate><creator>CHOW, A.</creator><creator>WIN, N. N.</creator><creator>NG, P. Y.</creator><creator>LEE, W.</creator><creator>WIN, M. K.</creator><general>Cambridge University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>7U2</scope><scope>5PM</scope></search><sort><creationdate>20160901</creationdate><title>Vancomycin-resistant enterococci with reduced daptomycin susceptibility in Singapore</title><author>CHOW, A. ; WIN, N. N. ; NG, P. Y. ; LEE, W. ; WIN, M. K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c482t-216a0d0b44b65b73efb969158b00e36c72bdbb47d6ec093a91bbae2dbe59277d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibiotics</topic><topic>Case-Control Studies</topic><topic>Comorbidity</topic><topic>Daptomycin - pharmacology</topic><topic>Enteropathogens</topic><topic>Epidemiology</topic><topic>FDA approval</topic><topic>Female</topic><topic>Gram-Positive Bacterial Infections - epidemiology</topic><topic>Gram-Positive Bacterial Infections - microbiology</topic><topic>Hospitalization</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nosocomial infections</topic><topic>Original Papers</topic><topic>Patients</topic><topic>Prevalence</topic><topic>Risk</topic><topic>Singapore - epidemiology</topic><topic>Tertiary Care Centers</topic><topic>Vancomycin Resistance</topic><topic>Vancomycin-Resistant Enterococci - drug effects</topic><topic>Vancomycin-Resistant Enterococci - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHOW, A.</creatorcontrib><creatorcontrib>WIN, N. N.</creatorcontrib><creatorcontrib>NG, P. Y.</creatorcontrib><creatorcontrib>LEE, W.</creatorcontrib><creatorcontrib>WIN, M. K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>Safety Science and Risk</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Epidemiology and infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHOW, A.</au><au>WIN, N. N.</au><au>NG, P. Y.</au><au>LEE, W.</au><au>WIN, M. K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vancomycin-resistant enterococci with reduced daptomycin susceptibility in Singapore: prevalence and associated factors</atitle><jtitle>Epidemiology and infection</jtitle><addtitle>Epidemiol Infect</addtitle><date>2016-09-01</date><risdate>2016</risdate><volume>144</volume><issue>12</issue><spage>2540</spage><epage>2545</epage><pages>2540-2545</pages><issn>0950-2688</issn><issn>1469-4409</issn><eissn>1469-4409</eissn><abstract>Prevalence of vancomycin-resistant enterococci (VRE) and use of daptomycin are increasing in Asia. To determine the prevalence of daptomycin non-susceptible enterococci (DNSE) and understand factors associated with reduced daptomycin susceptibility in VRE, we conducted a case-control study in a 1600-bed adult tertiary hospital in Singapore. All VRE isolates from inpatients in 2012 were tested for daptomycin susceptibility. Patients with VRE isolates of daptomycin minimum inhibitory concentration (MIC) 53 μg/ml were classified as daptomycinreduced susceptible VRE (DRS-VRE) and those with daptomycin MIC <3 μg/ml classified as daptomycin-susceptible VRE (DS-VRE). Medical records were reviewed for clinical and epidemiological data. None of 243 VRE isolates had MIC >4 μg/ml (DNSE). About half (135, 55%) had reduced susceptibility to daptomycin (MIC 3–4 μg/ml). None in the DS-VRE group had prior exposure to daptomycin. After adjusting for age, gender, comorbidity, hospitalization duration, surgical history, indwelling device use, and duration of antibiotic exposure in the prior 3 months, >1 movement between wards [odds ratio (OR) 0·35, 95% confidence interval (CI) 0·16–0·74, P = 0·006] and minocycline resistance (OR 0·45, 95% CI 0·25–0·84, P = 0·011) were independently associated with DRS-VRE. Our study suggests that daptomycin exposure, >1 movement between wards, and resistance to minocycline, were associated with reduced daptomycin susceptibility in VRE.</abstract><cop>England</cop><pub>Cambridge University Press</pub><pmid>27174845</pmid><doi>10.1017/S0950268816000923</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0950-2688 |
| ispartof | Epidemiology and infection, 2016-09, Vol.144 (12), p.2540-2545 |
| issn | 0950-2688 1469-4409 1469-4409 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9150451 |
| source | MEDLINE; Jstor Complete Legacy; PubMed Central |
| subjects | Aged Aged, 80 and over Anti-Bacterial Agents - pharmacology Antibiotics Case-Control Studies Comorbidity Daptomycin - pharmacology Enteropathogens Epidemiology FDA approval Female Gram-Positive Bacterial Infections - epidemiology Gram-Positive Bacterial Infections - microbiology Hospitalization Hospitals Humans Male Middle Aged Nosocomial infections Original Papers Patients Prevalence Risk Singapore - epidemiology Tertiary Care Centers Vancomycin Resistance Vancomycin-Resistant Enterococci - drug effects Vancomycin-Resistant Enterococci - physiology |
| title | Vancomycin-resistant enterococci with reduced daptomycin susceptibility in Singapore: prevalence and associated factors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T10%3A41%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vancomycin-resistant%20enterococci%20with%20reduced%20daptomycin%20susceptibility%20in%20Singapore:%20prevalence%20and%20associated%20factors&rft.jtitle=Epidemiology%20and%20infection&rft.au=CHOW,%20A.&rft.date=2016-09-01&rft.volume=144&rft.issue=12&rft.spage=2540&rft.epage=2545&rft.pages=2540-2545&rft.issn=0950-2688&rft.eissn=1469-4409&rft_id=info:doi/10.1017/S0950268816000923&rft_dat=%3Cjstor_pubme%3E26515768%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1808218657&rft_id=info:pmid/27174845&rft_jstor_id=26515768&rfr_iscdi=true |